Kingdon Capital Management’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Kingdon Capital Management’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-263,827	Closed	-$1.16M	–	177
2015 Q1	$1.16M	Sell	263,827 -22,974	-8%	-$115K	0.05%	144
2014 Q4	$1.38M	Hold	286,801	–	–	0.06%	135
2014 Q3	$1.17M	Hold	286,801	–	–	0.05%	149
2014 Q2	$1.67M	Sell	286,801 -15,000	-5%	-$85.1K	0.06%	170
2014 Q1	$1.93M	Sell	301,801 -113,199	-27%	-$1.02M	0.1%	157
2013 Q4	$3.95M	Buy	+415,000	New	+$3.24M	0.18%	141

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCA

Catalyst Capital Advisors Huntington, New York $6.03B AUM 24.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Kingdon Capital Management's TLOG Position: Q2 2015 in Review

Kingdon Capital Management sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2015, closing a stake of 263,827 shares — an estimated $1.16M sold.

Kingdon Capital Management first reported a position in TLOG in Q4 2013 and held it in 6 quarters. The position peaked at $3.95M in Q4 2013. 33 funds tracked by Wall St. Rank hold TLOG as of Q2 2015.

Kingdon Capital Management reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2015 after selling out during the quarter.
Kingdon Capital Management sold 263,827 TetraLogic Pharmaceuticals Corporation shares in Q2 2015, an estimated $1.16M.
Kingdon Capital Management first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 6 quarters.
Kingdon Capital Management's TetraLogic Pharmaceuticals Corporation position peaked at $3.95M in Q4 2013.
33 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2015.

Based on Kingdon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.